Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| But if you see how the BGT business is divided, we have market leadership in spine where we have not just an advantage from the technology perspective, but also from the infrastructure perspective |
| We sequentially improved adjusted EBITDA every quarter and exited the year with adjusted EBITDA expansion of 440 basis points as we saw the realization of cost synergies |
| For the full-year, non-GAAP adjusted EBITDA was $46.3 million or 6.2% of net sales, a 230 basis point improvement driven by higher gross margins and merger related synergies |
| The company has strong fundamentals and I believe great potential for future value creation |
| Yes, the company has been through much change in the last 12 months, but our business fundamentals have remained strong and our talented leaders and committed employees have executed exceptionally well |
| We executed against our guidance, gained momentum and accelerated strategic initiatives |
| Overall, we are pleased with our fourth quarter and 2023 results |
| During the last eight weeks, I've had the chance to speak to many stakeholders and are more encouraged than ever about the opportunity for growth and value creation that is in front of us |
| with 11.1% growth driven by strong performance with our new TrueLok EVO and our trauma solutions as well as distributor expansion and sales channel investments that remain in 2022 and 2023 and best-in-class surgeon education programs |
| This gives us confidence in our ability to deliver profitable revenue growth as we move into 2024 |
| I'm confident in our fundamental strategy across Orthopedics, Spine, Biologics, and Bone Growth Therapies |
| There should be no misgiving about the ability of this company to serve the evolving clinical needs of surgeons and patients, while also delivering strong growth combined with improved operational efficiencies |
| We performed well throughout 2023, gaining market share and maintaining a relationship with our partners |
| We are pleased that we have been able to maintain existing and build new relationships with our key distributor partners |
| At the midpoint of our guidance, our 2024 non-GAAP adjusted EBITDA guidance represents more than 400 basis points of EBITDA margin improvement over the first two years, 2023 and 2024, post close of the merger |
| spine fixation revenue grew 13.5% in the quarter, which is well above market growth rate |
| We have seen great performance with the AccelStim product and from our continued investment in a focused sales channel for the fracture market with growth of 23.6% in the fourth quarter |
| With last year's business combination, Orthofix brought together uniquely complementary best-in-class portfolios to create a compelling product platform across Spine and Orthopedics |
| We are well-positioned to capture value within specialized market and have already seen the inherent cross selling benefit of being able to leverage our portfolios as a whole |
| Look, there is a lot of excitement about what we're doing today around spine and orthopedics, and we have a very healthy pipeline |
| The fourth quarter marked four consecutive quarters of double-digit growth for the BGT franchise |
| Bone Growth Therapies revenue grew 15.3% to $58.8 million in Q4 and delivered 13.5% growth for the full-year 2023 |
| The merger between Orthofix and SeaSpine also created a biologics business unit with best-in-class products in the three of the most significant bone substitute segments: Cellular bone matrices, Demineralized bone matrices, and Synthetic bone substitutes |
| As noted earlier in the call, Orthofix finished the year with a strong fourth quarter |
| Furthermore, biologics is a capital efficient unit, ultimately driving cash and EBITDA gains for the company |
| Orthofix is a very solid footing and I anticipate being able to share a pleasingly meaningful update about the opportunities as we move into the next chapter of our story |
| Moving to Bone Growth Therapies or BGT, this business is well-positioned to continue growing the market and take share |
| In addition, the opportunity to support acute trauma with our AccelStim solution is propelling the growth of this franchise to relevant market |
| But I said during, something is important to notice that, 7D has been a great contributor of the success of the spine franchise even the last year, like we had 29%, if I remember of the overall revenue that came from 7D |
| The Orthopedics business has an impressive portfolio and pipeline of highly specialized internal and external solutions for complex limb reconstruction and deformity correction |
| Statement |
|---|
| We expect Q1 and Q2 revenue to be slightly below our full-year growth guidance range due to the timing of stocking orders in 2023 |
| This represented a 41% drop through on incremental revenue dollars |
| Let's say euro MDR costs come down a little bit |
| I think I was muted |
| I want to quell any notion that Orthofix is losing distributors |
| Just, I know this is, you're not giving line-by-line guidance by division, but the numbers do look somewhat conservative |
| Some factors that could cause actual results to be materially different from the forward-looking statements made by us on the call include the risk factors disclosed under the heading Risk Factors in our Form 10-K filed this afternoon, March 5, 2024, for the year ended December 31, 2023 as well as additional SEC filings we make in the future |
| GAAP, general and administrative expenses were 17.2% of net sales for Q4 2023, down from 20.8% in the same quarter prior year |
Please consider a small donation if you think this website provides you with relevant information